Just my take on MSB:
With all the LVAD issues. I'm waiting for news on the pre-BLA meeting. Which was targeted for Q4 CY2018;
I think the delay may be one FDA and MSB planning the commercial side of things like pricing and product launch. (Using Temsell Japan as a guide to determine commercial strategy for the US)
If this gets sorted out the Sp will jump. We are also waiting on the low back pain. News surely will come out within 6 months.
With the big ticket, 'Heart', end of 2019 or early 2020.
Bio stocks are risky but MSB is worth the risk.
With all the selling and negativity. One thing I don't want to hear is a a big fund manager has sold!
(20min delay)